Sanofi (SNY)

NASDAQ: SNY · USD

—

영어 원본으로 대체KO

번역하는 동안 영어 원본을 표시 중

이 리포트는 아직 번역되지 않았습니다. 번역 대기열이 따라잡으면 몇 분 후에 새로고침하세요.

StockMarketAgent Research · Analyzed 2026-05-20

Our latest published analysis: SNY rated Buy

Sanofi's published Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$51.2 / share

Potential value

$57.9 / share

Upside to FV

+17.5%

Moat

6.3/10

Narrow

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$104.3B
P/E (forward)	8.4x

Market data

Price

Recent price action with selectable time range.

Financial snapshot

P/E (forward): 8.4x
Market cap: $104.3B

Item	P1	P2	P3	P4	Trend
Period	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$40.56B	$41.62B	$44.29B	$46.72B	+4.8%
Gross profit	$28.68B	$28.99B	$31.08B	$33.67B	+5.5%
Operating income	$10.40B	$6.89B	$7.40B	$6.80B	-13.2%
Net income	$8.37B	$5.40B	$5.56B	$7.81B	-2.3%
EPS (diluted)	$2.69	$2.16	$2.30	$3.20	+6.0%
EBITDA	$13.51B	$11.32B	$10.99B	$12.48B	-2.6%
R&D	$6.50B	$6.51B	$7.39B	$7.84B	+6.5%
SG&A	$8.74B	$9.48B	$9.82B	$10.24B	+5.4%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ABBV	AbbVie Inc.	—	—	—	—	—	—	매도
ABT	Abbott Laboratories	—	—	—	—	—	—	비중 축소
ACN	Accenture plc	—	—	—	—	—	—	보유
ALGN	Align Technology Inc.	—	—	—	—	—	—	비중 축소
ALNY	Alnylam Pharmaceuticals, Inc.	—	—	—	—	—	—	적극 매수
AMGN	Amgen Inc.	—	—	—	—	—	—	매수

Base and Bull scenarios

Bull20%

Price target

$57.92

+33.0% from spot

Revenue accelerates beyond the historical 4.82% CAGR toward the 6.12% next-year estimate, driven by successful pipeline commercialization. Operating margins improve past 20%, and the equity partially re-rates toward the peer median.

Revenue accelerates beyond historical 4.82% CAGR.
Operating margins improve past 20.0%.
Market re-rates equity closer to peer median.

Base60%

Price target

$51.16

+17.5% from spot

Growth remains stable, anchored by vaccines and rare diseases. The 12.0x terminal multiple reflects a conservative partial re-rating from the current 8.4x, deliberately constrained below peers due to the rigid 97.7% dividend payout policy.

Revenue growth stable at mid single digits (2.5% terminal).
Operating margin maintained at exactly 20.0%.
Terminal multiple capped conservatively at 12.0x.

Sensitivity: Ke × terminal growth

The highlighted base cell is anchored to composite fair-value midpoint ($51.15). It is the reference value for this grid, not a separate standalone fair-value claim.

Ke ↓ / g →	1.5%	2.0%	2.5%	3.0%	3.5%
6.3%	$61.9	$69.2	$78.4	$89.5	$89.5
7.3%	$51.2	$56.0	$61.9	$69.2	$78.4
8.3%	$43.6	$47.1	$51.2	$56.0	$61.9
9.3%	$38.0	$40.6	$43.6	$47.1	$51.2
10.3%	$33.6	$35.7	$38.0	$40.6	$43.6

Scorecard

Published factor rows and weighted composite

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Forward P/E8.4

P25 n/aP50 n/aP75 n/a

Trailing P/E18.9

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROICn/a

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

Deeper analysis on SNY

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Quote this valuation with its source: Fair value, Potential value and the price at analysis.

Frequently asked questions

About this SNY report

What is the latest published SNY stock rating?

Sanofi is shown with Buy in the latest published report, analyzed 2026-05-20. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full SNY analysis?

The full latest published report, analyzed 2026-05-20, lives at /stocks/SNY/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for SNY?

The latest published report analyzed 2026-05-20 gives SNY a fair value of USD 51 and a potential value of USD 58. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the SNY page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-05-20). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

BuySNY · Fair value $51.2+17.5%

Read full analysis →

Category	Score	Reading
Valuation	7.5
Management	7.3
Balance Sheet	7.0
Profitability	5.5
Revenue Growth	6.0
Risk Assessment	8.5
Competitive Moat	6.3
Earnings Quality	6.0
Capital Efficiency	5.0

Sanofi (SNY)

Our latest published analysis: SNY rated Buy

Price

Financial snapshot

Fair-value bridge

Latest news · SNY

Valuation

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

Deeper analysis on SNY

Frequently asked questions

등급 이력